Developmental skeletal anomalies

Birth Defects Research Part C - Embryo Today: Reviews

Volumn 69, Issue 2, 2003, Pages 197-207

  Morcuende, Jose A ^a,b   Weinstein, Stuart L ^a  

^a UNIVERSITY OF IOWA   (United States)

^b Dept of Orthoped Surg and Rehab ^*  (United States)

Author keywords

Clubfoot; Developmental dislocation of the hip; Skeletal dysplasias; Spinal deformities

Indexed keywords

ANIMAL MODEL; BONE DEVELOPMENT; BONE DYSPLASIA; CLUBFOOT; GENE THERAPY; HIP DISLOCATION; HUMAN; MEDICAL GENETICS; MEDICAL INFORMATION; MOLECULAR BIOLOGY; MUSCULOSKELETAL DISEASE; MUTATION; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SKELETON MALFORMATION; SPINE MALFORMATION;

BONE AND BONES; BONE DISEASES, DEVELOPMENTAL; HUMANS;

ANIMALIA;

EID: 0141959074     PISSN: 1542975X     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdrc.10011     Document Type: Review

References (117)

1. Ahn J et al. 1995. Cloning of the putative tumor suppressor gene for hereditary multiple exostoses (EXT1). Nat Genet 11:137-143.
2. Aikawa T, Segre GV, Lee K. 2001. Fibroblast growth factor inhibits chondrocytic growth through induction of p21 and subsequent inactivation of cyclin E-Cdk2. J Biol Chem 276:29347-29352.
3. Aronson J, Puskarich CL. 1990. Deformity and disability from treated clubfoot. J Pediatr Orthop 10:109.
4. Astrom E, Soderhall S. 1998. Beneficial effects of biphosphonate during five years of treatment of severe osteogenesis imperfecta. Acta Paediatr 87: 64-68.
5. Atar D, Lehman WB, Grant AD. 1991. Complications in clubfoot surgery. Orthop Rev 20:233-239.
6. Atar D et al. 1992. Revision surgery in clubfoot. Clin Orthop Relat Res 283: 223-230.
7. Barsh GS et al. 1985. Intron-mediated recombination may cause a delection in an alpha 1 type I collagen chain in a lethal form of osteogenesis imperfecta. Proc Natl Acad Sci U S A 82: 2870-2874.
8. Basilico C, Moscatelli D. 1992. The FGF family of growth factors and oncogenes. Adv Cancer Res 59:115-165.
9. Bellaiche Y, The I, Perrimon N. 1998. Tout-velu is a Drosophila homologue of the putative tumour suppressor EXT-1 and is needed for Hh diffusion. Nature 394:85-88.
10. Bellus GA et al. 1995. A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia. Nat Genet 10:357-359.
11. Bembi B et al. 1997. Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr 131:622-625.
12. Bennet GC. 1992. Screening for congenital dislocation of the hip. J Bone Joint Surg 74B:643-644.
13. Bitgood MJ, McMahon AP. 1995. Hedge-hog and Bmp genes are co-expressed at many diverse sites of cell-cell interaction in the mouse embryo. Dev Biol 172:126-138.
14. Bovee JV et al. 1999. EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas. Am J Hum Genet 65:689-698.
15. Boyadjiev SA, Jabs EW. 2000. Online Mendelian Inheritance in Man (OMIM) as a knowledgebase for human developmental disorders. Clin Genet 57: 253-266.
16. Catterall A. 1994. The early diagnosis of congenital dislocation of the hip. J Bone Joint Surg 76B:515-516.
17. Chen L, Li C, Qiao W et al. 2001. A Ser(365) to Cys mutation of fibroblast growth factor receptor 3 in mouse downregulates Ihh/PTHrP signals and causes severe achondroplasia. Hum Mol Genet 10:457-465.
18. Chisaka C, Capecchi MR. 1991. Regionality restricted developmental defects resulting from targeted disruption of the mouse homeobox gene hox-15. Nature 350:473-479.
19. Chu ML, Gargiulo V, Williams CJ, Ramirez F. 1985. Multiexon deletion in a osteogenesis imperfecta variant with increased type III collagen mRNA. J Biol Chem 260:691-694.
20. Clines GA et al. 1997. The structure of the human multiple exostoses 2 gene and characterization of homologs in mouse and Caenorhabditis elegans. Genome Res 7:359-367.
21. Cohn DH, Zhang X, Byers PH. 1993. Homology-mediated recombination between type I collagen gene exons results in an internal tandem duplication and lethal osteogenesis imperfecta. Hum Mutat 2:21-27.
22. Cole WG. 2002. Advances in osteogenesis imperfecta. Clin Ortho Relat Res 401:6-16.
23. Coleman SS. 1994. Developmental dislocation of the hip: evolutionary changes in diagnosis and treatment. J Pediatr Orthop 14:1-2.
24. Colin S et al. 1999. In vivo involvement of heparan sulfate proteoglycan in the bioavailability, internalization, and catabolism of exogenous basic fibroblast growth factor. Mol Pharmacol 55: 74-82.
25. Colvin JS et al. 1996. Skeletal over-growth and deafness in mice lacking fibroblast growth factor receptor 3. Nat Genet 12:390-397.
26. Cooper DM, Dietz FR. 1995. Treatment of idiopathic clubfoot. A thirty-year follow-up note. J Bone Joint Surg 77A: 1477-1489.
27. Deng C et al. 1996. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84:911-921.
28. Devogelaer JP et al. 1987. Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol 16:360-363.
29. Dietrich S, Kessel M. 1997. The vertebral column. In: Thorogood P, editor. Embryos, genes, and birth defects. John Wiley and Sons Ltd. p 281-302.
30. Duncan G, McCormick C, Tufaro F. 2001. The link between heparan sulfate and hereditary bone disease: finding a function for the EXT family of putative tumor suppressor proteins. J Clin Invest 108:511-516.
31. Gardner WJ. 1964. Diastomatomyelia and Klipper-Feil syndrome. Relationship to hydrocephalus, syringomyelia, meningocele, meningomyelocele, and iniencephalus. Clev Clin 31:19-25.
32. Gardner WJ. 1973. The dysraphic states from syringomyelia to anencephaly. Amsterdam: Excerpta Medica.
33. George TM, McLone DG. 1995. Mechanisms of mutant genes in spina bifida: a review of implications from animal model. Pediatr Neurosurg 23:236-245.
34. Givol D, Yayon A. 1992. Complexity of FGF receptors: genetic basis for structural diversity. FASEB J. 6:3362-3369.
35. Glorieux FH et al. 1998. Cyclic administration of Pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947-952.
36. Glorieux FH. 2000. Bisphosphonate therapy for severe osteogenesis imperfecta. J Pediatr Endocrinol Metab 13:989-992.
37. Glorieux FH et al. 2000. Type V osteogenesis imperfecta: a new form of brittle bone disease. J Bone Miner Res 15:1650-1658.
38. Godward S, Dezateux C. 1998. Surgery for congenital dislocation of the hip in the UK as a measure of outcome of screening. Lancet 351:1149-1152.
39. Grassi G, Marini JC. 1996. Ribozymes: structure, function, and potential therapy for dominant genetic disorders. Ann Med 28:499-510.
40. Green PI, Walsh FS, Doherty P. 1996. Promiscuity of fibroblast growth factor receptors. Bioessays 18:639-646.
41. Gritli-Linde A et al. 2001. The where-abouts of a morphogen: direct evidence for short- and graded long-range activity of hedgehog signaling peptides. Dev Biol 236:364-86.
42. Haack H, Kessel M. 1994. Homeobox genes and skeletal patterning. In: Hall BK, editor. Bone. Vol. IX. CRC Press: Boca Raton. p 119-144.
43. Hecht JT et al. 1995. Hereditary multiple exostosis and chondrosarcoma: linkage to chromosome II and loss of heterozygosity for EXT-linked markers on chromosomes II and 8. Am J Hum Genet 56:1125-1131.
44. Hecht JT et al. 1997. Hereditary multiple exostoses (EXT): mutational studies of familial EXT1 cases and EXT-associated malignancies. Am J Hum Genet 60:80-86.
45. Hennekam RC. 1991. Hereditary multiple exostoses. J Med Genet 28:262-266.
46. Horton WA. 1995. Molecular genetics of the human chondrodysplasias. Eur J Hum Genet 3:357-373.
47. Horwitz EM et al. 1999. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 5:309-313.
48. Horwitz EM et al. 2001. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 97:1227-1231.
49. Johnson DE, Williams LT. 1993. Structural and functional diversity in the FGF receptor multi gene family. Adv Cancer Res 60:1-41.
50. Kessel M, Gruss P. 1991. Homeotic transformation of murine vertebrae and concomitant alteration of Hox codes induced by retinoic acid. Cell 67:89-104.
51. Kessel M. 1994. Respecification of vertebral identities by retinoic acid. Development 115:487-501.
52. Kim BT et al. 2002. Demonstration of a novel gene DEXT3 of Drosophila melanogaster as the essential N-acetylglucosamine transferase in the heparan sulfate biosynthesis: chain initiation and elongation. J Biol Chem 277:13659-13665.
53. Knudson Jr AG. 1971. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 68: 820-823.
54. Landsmeer-Beker E et al. 1997. Treatment of osteogenesis imperfecta with bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate). Eur J Pediatr 156:792-794.
55. Le Merrer M et al. 1994. A gene for hereditary multiple exostoses maps to chromosome 19p. Hum Mol Genet 3: 717-722.
56. Legeai-Mallet L et al. 1997. Incomplete penetrance and expressivity skewing in hereditary multiple exostoses. Clin Genet 52:12-16.
57. Li C et al. 1999. A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors. Hum Mol Genet 8:35-44.
58. Ligon AH et al. 1998. Gene for multiple exostoses (EXT2) maps to 11(p11.2p12) and is deleted in patients with a contiguous gene syndrome. Am J Med Genet 75:538-540.
59. Lin X, Wells D. 1997. Isolation of the mouse cDNA homologous to the human EXT1 gene responsible for hereditary multiple exostoses. DNA Seq 7: 199-202.
60. Lin X et al. 1998. Expression and functional analysis of mouse EXT1, a homolog of the human multiple exostoses type 1 gene. Biochem Biophys Res Commun 248:738-743.
61. Lin X et al. 2000. Disruption of gastrulation and heparan sulfate biosynthesis in EXT1-deficient mice. Dev Biol 224:299-311.
62. Ludecke HI et al. 1995. Molecular dissection of a contiguous gene syndrome: localization of the genes involved in the Langer-Giedion syndrome. Hum Mol Genet 4:31-36.
63. Marini JC, Gerber NL. 1997. Osteogenesis imperfecta: rehabilitation and prospects for gene therapy. JAMA 277: 746-750.
64. Martin GR. 1998. The roles of FGFs in the early development of vertebrate limbs. Genes Dev 12:1571-1586.
65. McCormick C et al. 1998. The putative tumour suppressor EXT1 alters the expression of cell-surface heparan sulfate. Nat Genet 19:158-161.
66. McCormick C et al. 2000a. The putative tumor suppressors EXT1 and EXT2 form a stable complex that accumulates in the Golgi apparatus and catalyzes the synthesis of heparan sulfate. Proc Natl Acad Sci U S A 97:668-673.
67. McCormick C, Duncan G, Tufaro F. 2000b. Herpes simplex virus: discovering the link between heparan sulphate and hereditary bone tumours. Rev Med Virol 10:373-384.
68. McGinnis W, Krumlauf R. 1992. Homeobox genes and axial patterning. Cell: 68:283-302.
69. Mertens F et al. 1994. Loss of chromosome band 8q24 in sporadic osteocartilaginous exostoses. Genes Chromosomes Cancer 9:8-12.
70. Mundlos S et al. 1996. Multiexon deletions in the type I collagen COL1A2 gene in osteogenesis imperfecta type IIB: molecules containing the shortened α2(1)-chains show differential incorporation into the bone and skin extracellular matrix. J Biol Chem 271: 21068-21074.
71. Naski MC, Wang Q, Xu J, Ornitz DM. 1996. Graded activation of fibroblast growth factor receptor 3 by mutatitons causing achondroplasia and thanatophoricdysplasia. Nat Genet 13: 233-237.
72. Naski MC et al. 1998. Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. Development 12:4977-4988.
73. Partington MD, McLone DG. 1995. Hereditary factors in the etiology of neural tube defects. Pediatr Neurosurg 23: 311-315.
74. Pathi S, et al. 2001. Comparative biological responses to human Sonic, Indian, and Desert hedgehog. Mech Dev 106:107-117.
75. Pereira RF et al. 1998. Marrow stromal cells as a source of progenitor cells for non-hematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta. Proc Natl Acad Sci U S A 95:1142-1147.
76. Plotkin H et al. 2000. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 85:1846-1850.
77. Ponseti IV. 1989. Fifty years of orthopaedics. J Pediatr Orthop 9:79-85.
78. Ponseti IV. 1996. Congenital clubfoot. Fundamentals of treatment. Oxford Medical Publications. New York.
79. Porter DE, Simpson AH. 1999. The neoplastic pathogenesis of solitary and multiple osteochondromas. J Pathol 188:119-125.
80. Prockop DJ. 1997. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276:71-74.
81. Prockop DJ. 1998. Marrow stromal cells as stem cells for continual renewal of nonhematopoietic tissues and as a potential vectors for gene therapy. J Cell Biochem 31:284-285.
82. Prockop DJ et al. 2000. Potential use of stem cells from bone marrow to repair the extracellular matrix and the central nervous system. Biochem Soc Trans 28:341-345.
83. Raskind WH et al. 1995. Loss of heterozygosity in chondrosarcomas for markers linked to hereditary multiple exostoses loci on chromosomes 8 and 11. Am J Hum Genet 56:1132-1139.
84. Rebbeck TR et al. 1993. A single gene explanation for the probability of having idiopathic talipes equinovarus. Am J Hum Genet 53:1051-1063.
85. Rousseau F et al. 1994. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 371:252-254.
86. Rousseau F et al. 1996. Mutations of the fibroblast growth factor receptor-3 gene in achondroplasia. Horm Res 45: 108-110.
87. Sahni M et al. 1999. FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev 13:1361-1366.
88. Saito T et al. 1998. Structure, chromosomal location, and expression profile of EXTR1 and EXTR2, new members of the multiple exostoses gene family. Biochem Biophys Res Commun 243: 61-66.
89. Sakai LY et al. 1996. Current knowledge and research directions in heritable disorders of connective tissue. Matrix Biol 15:211-229.
90. Schlessinger J, Lax I, Lemmon M. 1995. Regulation of growth factor activation by proteoglycans: what is the role of the low affinity receptors? Cell 83:357-360.
91. Schmale GA, Conrad EU, Raskind WH. 1994. The natural history of hereditary multiple exostoses. J Bone Joint Surg Am 76:986-992.
92. Shiang R et al. 1994. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 78: 335-342.
93. Sillence DO, Rimoin DL, Danks DM. 1979. Clinical variability in osteogenesis imperfecta-variable expressivity or genetic heterogeneity. Birth Defects Orig Artic Ser 15(5B):113-129.
94. Stickens D, Evans GA. 1997. Isolation and characterization of the murine homolog of the human EXT2 multiple exostoses gene. Biochem Mol Med 61: 16-21.
95. Su WC et al. 1997. Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. Nature 386:288-292.
96. Sullivan JA. 1996. The children's foot. In: Morrissy RT, Weinstein SL, editors. Lovell and Winter's pediatric orthopaedics. The Child's Foot. 4th ed. Lippincott-Raven, Philadelphia. p 114-116.
97. Superti-Furga A, Bonafe L, Rimoin DL. 2001. Molecular-pathogenetic classification of genetic disorders of the skeleton. Am J Med Genet 106:282-293.
98. Tavormina PL et al. 1995a. Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I. Hum Mol Genet 4:2175-2177.
99. Tavormina PL et al. 1995b. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat Genet 9:321-328.
100. Vajo Z, Francomano CA, Wilkin DJ. 2002. The molecular and genetic basis of fibroblast growth factor receptor 3 disorders the achondroplasia family of skeletal dysplasias, Muenke carniosynostosis, and Crouzon syndrome with acanthosis nigricans. Endocrine Rev 21:23-39.
101. Van Hul W et al. 1998. Identification of a third EXT-like gene (EXTL3) belonging to the EXT gene family. Genomics 47: 230-237.
102. Vetter U et al. 1991. Osteogenesis imperfecta: changes in noncollageneous proteins in bone. J Bone Miner Res 6:501-505.
103. Voutsinas S, Wynne-Davies R. 1983. The infrequency of malignant disease in diaphyseal aclasis and neurofibromatosis. J Med Genet 20:345-349.
104. Wang Q, Marini JC. 1996. Antisense oligodeoxynucleotides selectively suppress expression of the mutant alpha 2(I) collagen allele in type IV osteogenesis imperfecta fibroblasts: a molecular approach to therapeutics of dominant negative disorders. J Clin Invest 97:448-454.
105. Wang Y et al. 1999. A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3. Proc Natl Acad Sci U S A 96:4455-4460.
106. Webster MK et al. 1996. Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II. Mol Cell Biol 16:4081-4087.
107. Webster MK, Donoghue DJ. 1996a. Fibroblast growth factor receptor 3 is constitutively activated by independent mechanisms in two skeletal dysplasias. Proc Annu Meet Am Assoc Cancer Res 37:A264.
108. Webster MK, Donoghue DJ. 1996b. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO J 15: 520-527.
109. Webster MK, Donoghue DJ. 1997. FGFR activation in skeletal disorders: too much of a good thing. Trends Genet 13:178-182.
110. Weinstein SL. 1996. Developmental hip dysplasia and dislocation. In: Norrissy RT, Weinstein SL, editors. Lovell and Winter's pediatric orthopaedics. 4th ed. Lippincott-Raven, Philadelphia. p 903-950.
111. Wicklund CL et al. 1995. Natural history study of hereditary multiple exostoses. Am J Med Genet 55:43-46.
112. Willing MC et al. 1988. Heterozygosity for a large delection in the α2(1) collagen gene has a dramatic effect on type I collagen secretion and produces perinatal lethal osteogenesis imperfecta. J Biol Chem 263;8398-8404.
113. Willing MC et al. 1996. Premature chain termination is a unifying mechanism for COL1A1 null alleles in osteogenesis imperfecta type I cell strains. Am J Hum Genet 59:799-809.
114. Wise CA et al. 1997. Identification and localization of the gene for EXTL, a third member of the multiple exostoses gene family. Genome Res 7:10-16.
115. Wuyts W et al. 1995. Refinement of the multiple exostoses locus (EXT2) to a 3-cM interval on chromosome 11. Am J Hum Genet 57:382-387.
116. Wuyts W, Van Hul W. 2000. Characterization and genomic localization of the mouse Extl2 gene. Cytogenet Cell Genet 89:185-188.
117. Zeltser L, Desplan C, Heintz N. 1996. Hoxb-13: a new Hox gene in a distant region of the HoxB cluster maintains colinearity. Development 122:2475-2484.